Skip to main content
Premium Trial:

Request an Annual Quote

Steve Lundy, W. David Henner, David Craford

Ciphergen has named Steve Lundy senior vice president of sales and marketing, the company said this week.
 
Lundy comes to Ciphergen from GeneOhm, where he was vice president of sales and marketing. GeneOhm was acquired last year by Becton Dickinson. He had worked earlier as vice president of marketing at Esoterix and was marketing director of molecular diagnostics and critical care testing at Bayer Diagnostics.
 

 
Pathwork Diagnostics has appointed W. David Henner chief medical officer, and it has named David Craford vice president of commercial operations.
 
Henner formerly was vice president of oncology at Novacea, and Craford previously served as vice president of business development at Affymetrix.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.